NCT05500170 Benefits of Nicotinamide Riboside Upon Cognition and Sleep
| NCT ID | NCT05500170 |
| Status | Recruiting |
| Phase | — |
| Sponsor | State University of New York at Buffalo |
| Condition | Cognitive Impairment |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-04-04 |
| Primary Completion | 2027-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2023-04-04 with a primary completion date of 2027-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Poor sleep quality and short sleep duration may be a mechanistic component of cognitive impairment in older adults, associated with a decline in brain-derived neurotrophic factor. Increasing the availability of nicotinamide adenine dinucleotide (NAD+) with supplementation of its precursor, nicotinamide riboside (NR), a form of vitamin B3 may increase the expression of brain-derived neurotrophic factor. This study proposes to examine the benefits of NR supplementation on sleep and cognitive function in older adults with comprehensive subjective and objective measures and to explore its impacts on serum brain-derived neurotrophic factor.
Eligibility Criteria
Inclusion Criteria: * Sleep Quality. Pittsburgh Sleep Quality Index (PSQI) global score \>5 Exclusion Criteria: * Dementia. Veteran Affairs - St. Louis University Mental Status questionnaire (VA-SLUMS) score \<20
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05500170 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, up to 85 Years, studying Cognitive Impairment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05500170 currently recruiting?
Yes, NCT05500170 is actively recruiting participants. Contact the research team at carleara@buffalo.edu for enrollment information.
Where is the NCT05500170 trial being conducted?
This trial is being conducted at Buffalo, United States, Buffalo, United States, Buffalo, United States.
Who is sponsoring the NCT05500170 clinical trial?
NCT05500170 is sponsored by State University of New York at Buffalo. The trial plans to enroll 50 participants.